Creo Medical Group PLC Video abstracts re. Speedboat procedures in India

TIDMCREO

Creo Medical Group PLC

11 February 2020

Creo Medical Group plc

("Creo" or the "Company")

Video abstracts featuring Speedboat procedures in India

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that the Company's Speedboat device has featured in two newly published video abstracts published by clinicians from the Asian Institute of Gastroenterology, Hyderabad, India.

Both video abstracts were authored by experts in the field of Gastrointestinal ("GI") therapeutic endoscopy for the Asian Institute of Gastroenterology, Hyderabad, India. These procedures follow on from the first in-human use of the Speedboat device in India as announced in November last year, as well as additional procedures in multiple sites in the US, UK, Spain, South Africa and, more recently, Australia.

The first video abstract, published on Video GIE, the official video journal of the American Society of Gastrointestinal Endoscopy, is titled, "Peroral endoscopic myotomy in a patient with failed Heller's myotomy by use of a novel bipolar radiofrequency device." The abstract can be viewed on:

https://www.videogie.org/article/S2468-4481(19)30344-3/fulltext

The second video abstract, published via an open access content publisher, Thieme Group, is titled, "Endoscopic dissection of an esophageal submucosal tumor using a novel bipolar radiofrequency device" and can be viewed online here: https://www.thieme-connect.de/products/ejournals/html/10.1055/a-1089-7680

Craig Gulliford, Chief Executive Officer, commented: "We are delighted to see physicians from different parts of the world not only treating patients but quickly getting published in video form which really highlights the power of advanced energy in the flexible endoscopy setting. Particularly impressive is the size of blood vessels which are being managed with ease using microwave energy and our Speedboat where traditional technology would have struggled even with multiple devices being deployed."

 
 Creo Medical Group plc                                          investors.creomedical.com 
 Richard Rees (CFO)                                                    [phone] 
 
 Cenkos Securities                                                     [phone] 
 Stephen Keys / Cameron MacRitchie 
  (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Paul McManus / Lianne Cawthorne                    Mob: [phone] 
                                                                                   909 238 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAGZGMZGGFGGZZ

(END) Dow Jones Newswires

February 11, 2020 02:00 ET (07:00 GMT)